Reviewer’s report

Title: Effects of Lactobacillus salivarius-containing tablets on caries risk factors: open-label clinical trial

Version: 2 Date: 20 June 2014

Reviewer: Noriaki Kamio

Reviewer’s report:

The manuscript of Nishihara et al. describes administration of tablets containing L. salivarius WB21 and L. salivarius TI 2711 increased resistance to caries risk factors. The manuscript is very interesting and is of interest to readers. However, some questions remain to be addressed.

Minor

Comment #1

In Figure 1 legend, the authors describe “mutans streptococcus levels (A), lactobacillus levels (B)”. Did the authors mean “mutans streptococci levels (A), lactobacilli levels (B)” in this sentence?

Discretionary

Comment #2

The authors showed salivary flow, pH, and buffering capacity amounts assessed before and after taking the tablets. In short-term administration trial with L. salivarius WB21 tablet, the authors showed only the data of mutans streptococci levels. Do the authors have the data for salivary flow, pH, and buffering capacity in short-term administration trial with L. salivarius WB21 tablet?

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.